PMC:7205724 / 181-596
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3 | 71-78 | Species | denotes | patient | Tax:9606 |
5 | 150-158 | Disease | denotes | COVID-19 | MESH:C000657245 |
7 | 233-241 | Disease | denotes | COVID-19 | MESH:C000657245 |
10 | 246-249 | Gene | denotes | IL6 | Gene:3569 |
11 | 318-326 | Disease | denotes | COVID-19 | MESH:C000657245 |
17 | 352-355 | Gene | denotes | IL6 | Gene:3569 |
18 | 411-414 | Gene | denotes | IL6 | Gene:3569 |
19 | 379-387 | Species | denotes | patients | Tax:9606 |
20 | 331-342 | Chemical | denotes | Tocilizumab | MESH:C502936 |
21 | 393-401 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 150-158 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 233-241 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 318-326 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 393-401 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T3 | 40-55 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T4 | 103-118 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T5 | 213-228 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T2 | 289-299 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | viral load | http://purl.bioontology.org/ontology/MEDDRA/10062178 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T2 | 40-55 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T3 | 103-118 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T4 | 213-228 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T2 | 150-158 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T3 | 233-241 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T4 | 318-326 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T5 | 393-401 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 0-88 | Sentence | denotes | • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. |
T6 | 89-159 | Sentence | denotes | • The use of corticosteroids might accelerate recovery from COVID-19. |
T7 | 160-242 | Sentence | denotes | • No controlled clinical trials exist on the use of corticosteroids for COVID-19. |
T8 | 243-327 | Sentence | denotes | • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19. |
T9 | 328-415 | Sentence | denotes | • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
3 | 71-78 | Species | denotes | patient | Tax:9606 |
5 | 150-158 | Disease | denotes | COVID-19 | MESH:C000657245 |
7 | 233-241 | Disease | denotes | COVID-19 | MESH:C000657245 |
10 | 246-249 | Gene | denotes | IL6 | Gene:3569 |
11 | 318-326 | Disease | denotes | COVID-19 | MESH:C000657245 |
20 | 331-342 | Chemical | denotes | Tocilizumab | MESH:C502936 |
17 | 352-355 | Gene | denotes | IL6 | Gene:3569 |
19 | 379-387 | Species | denotes | patients | Tax:9606 |
21 | 393-401 | Disease | denotes | COVID-19 | MESH:C000657245 |
18 | 411-414 | Gene | denotes | IL6 | Gene:3569 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T1 | 246-249 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
T45 | 352-355 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
T89 | 411-414 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T24 | 0-1 | IN | denotes | • |
T25 | 3-7 | NNP | denotes | IVIG |
T26 | 7-8 | -COMMA- | denotes | , |
T27 | 9-17 | VBN | denotes | combined |
T28 | 18-22 | IN | denotes | with |
T29 | 23-36 | NN | denotes | moderate-dose |
T30 | 37-39 | IN | denotes | of |
T31 | 40-55 | NNS | denotes | corticosteroids |
T32 | 55-56 | -COMMA- | denotes | , |
T33 | 57-62 | MD | denotes | might |
T34 | 63-70 | VB | denotes | improve |
T35 | 71-78 | NN | denotes | patient |
T36 | 79-87 | NNS | denotes | outcomes |
T37 | 89-90 | PDT | denotes | • |
T38 | 92-95 | DT | denotes | The |
T39 | 96-99 | NN | denotes | use |
T40 | 100-102 | IN | denotes | of |
T41 | 103-118 | NNS | denotes | corticosteroids |
T42 | 119-124 | MD | denotes | might |
T43 | 125-135 | VB | denotes | accelerate |
T44 | 136-144 | NN | denotes | recovery |
T45 | 145-149 | IN | denotes | from |
T46 | 150-158 | NN | denotes | COVID-19 |
T47 | 160-161 | PDT | denotes | • |
T48 | 163-165 | DT | denotes | No |
T49 | 166-176 | VBN | denotes | controlled |
T50 | 177-185 | JJ | denotes | clinical |
T51 | 186-192 | NNS | denotes | trials |
T52 | 193-198 | VBP | denotes | exist |
T53 | 199-201 | IN | denotes | on |
T54 | 202-205 | DT | denotes | the |
T55 | 206-209 | NN | denotes | use |
T56 | 210-212 | IN | denotes | of |
T57 | 213-228 | NNS | denotes | corticosteroids |
T58 | 229-232 | IN | denotes | for |
T59 | 233-241 | NN | denotes | COVID-19 |
T60 | 243-244 | LS | denotes | • |
T61 | 246-249 | NN | denotes | IL6 |
T62 | 250-260 | VBZ | denotes | correlates |
T63 | 261-265 | IN | denotes | with |
T64 | 266-274 | NN | denotes | severity |
T65 | 274-275 | -COMMA- | denotes | , |
T66 | 276-287 | NN | denotes | criticality |
T67 | 287-288 | -COMMA- | denotes | , |
T68 | 289-294 | JJ | denotes | viral |
T69 | 295-299 | NN | denotes | load |
T70 | 299-300 | -COMMA- | denotes | , |
T71 | 301-304 | CC | denotes | and |
T72 | 305-314 | NN | denotes | prognosis |
T73 | 315-317 | IN | denotes | of |
T74 | 318-326 | NN | denotes | COVID-19 |
T75 | 328-329 | IN | denotes | • |
T76 | 331-342 | NNP | denotes | Tocilizumab |
T77 | 342-343 | -COMMA- | denotes | , |
T78 | 344-346 | DT | denotes | an |
T79 | 347-355 | NN | denotes | anti-IL6 |
T80 | 355-356 | -COMMA- | denotes | , |
T81 | 357-360 | MD | denotes | can |
T82 | 361-367 | VB | denotes | confer |
T83 | 368-375 | NN | denotes | benefit |
T84 | 376-378 | IN | denotes | in |
T85 | 379-387 | NNS | denotes | patients |
T86 | 388-392 | IN | denotes | with |
T87 | 393-401 | NN | denotes | COVID-19 |
T88 | 402-405 | CC | denotes | and |
T89 | 406-410 | JJ | denotes | high |
T90 | 411-414 | NN | denotes | IL6 |
R20 | T25 | T24 | arg1Of | IVIG,• |
R21 | T25 | T26 | arg1Of | IVIG,"," |
R22 | T25 | T27 | arg2Of | IVIG,combined |
R23 | T27 | T28 | arg1Of | combined,with |
R24 | T29 | T28 | arg2Of | moderate-dose,with |
R25 | T29 | T30 | arg1Of | moderate-dose,of |
R26 | T31 | T30 | arg2Of | corticosteroids,of |
R27 | T34 | T32 | arg1Of | improve,"," |
R28 | T25 | T33 | arg1Of | IVIG,might |
R29 | T34 | T33 | arg2Of | improve,might |
R30 | T25 | T34 | arg1Of | IVIG,improve |
R31 | T36 | T34 | arg2Of | outcomes,improve |
R32 | T36 | T35 | arg1Of | outcomes,patient |
R33 | T39 | T37 | arg1Of | use,• |
R34 | T39 | T38 | arg1Of | use,The |
R35 | T39 | T40 | arg1Of | use,of |
R36 | T41 | T40 | arg2Of | corticosteroids,of |
R37 | T39 | T42 | arg1Of | use,might |
R38 | T43 | T42 | arg2Of | accelerate,might |
R39 | T39 | T43 | arg1Of | use,accelerate |
R40 | T44 | T43 | arg2Of | recovery,accelerate |
R41 | T44 | T45 | arg1Of | recovery,from |
R42 | T46 | T45 | arg2Of | COVID-19,from |
R43 | T51 | T47 | arg1Of | trials,• |
R44 | T51 | T48 | arg1Of | trials,No |
R45 | T51 | T49 | arg2Of | trials,controlled |
R46 | T51 | T50 | arg1Of | trials,clinical |
R47 | T51 | T52 | arg1Of | trials,exist |
R48 | T52 | T53 | arg1Of | exist,on |
R49 | T55 | T53 | arg2Of | use,on |
R50 | T55 | T54 | arg1Of | use,the |
R51 | T55 | T56 | arg1Of | use,of |
R52 | T57 | T56 | arg2Of | corticosteroids,of |
R53 | T55 | T58 | arg1Of | use,for |
R54 | T59 | T58 | arg2Of | COVID-19,for |
R55 | T62 | T60 | arg1Of | correlates,• |
R56 | T61 | T62 | arg1Of | IL6,correlates |
R57 | T62 | T63 | arg1Of | correlates,with |
R58 | T71 | T63 | arg2Of | and,with |
R59 | T64 | T65 | arg1Of | severity,"," |
R60 | T66 | T65 | arg2Of | criticality,"," |
R61 | T65 | T67 | arg1Of | ",","," |
R62 | T69 | T67 | arg2Of | load,"," |
R63 | T69 | T68 | arg1Of | load,viral |
R64 | T71 | T70 | arg1Of | and,"," |
R65 | T67 | T71 | arg1Of | ",",and |
R66 | T72 | T71 | arg2Of | prognosis,and |
R67 | T72 | T73 | arg1Of | prognosis,of |
R68 | T74 | T73 | arg2Of | COVID-19,of |
R69 | T82 | T75 | arg1Of | confer,• |
R70 | T76 | T77 | arg1Of | Tocilizumab,"," |
R71 | T79 | T77 | arg2Of | anti-IL6,"," |
R72 | T79 | T78 | arg1Of | anti-IL6,an |
R73 | T82 | T80 | arg1Of | confer,"," |
R74 | T76 | T81 | arg1Of | Tocilizumab,can |
R75 | T82 | T81 | arg2Of | confer,can |
R76 | T76 | T82 | arg1Of | Tocilizumab,confer |
R77 | T83 | T82 | arg2Of | benefit,confer |
R78 | T82 | T84 | arg1Of | confer,in |
R79 | T85 | T84 | arg2Of | patients,in |
R80 | T85 | T86 | arg1Of | patients,with |
R81 | T88 | T86 | arg2Of | and,with |
R82 | T87 | T88 | arg1Of | COVID-19,and |
R83 | T90 | T88 | arg2Of | IL6,and |
R84 | T90 | T89 | arg1Of | IL6,high |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 150-158 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 233-241 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 318-326 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 393-401 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 0-88 | Sentence | denotes | • IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. |
T6 | 89-159 | Sentence | denotes | • The use of corticosteroids might accelerate recovery from COVID-19. |
T7 | 160-242 | Sentence | denotes | • No controlled clinical trials exist on the use of corticosteroids for COVID-19. |
T8 | 243-327 | Sentence | denotes | • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19. |
T9 | 328-415 | Sentence | denotes | • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6. |